Research progress on novel antibody drug conjugates in cancer therapy
10.11817/j.issn.1672-7347.2024.230418
- VernacularTitle:癌症治疗中新型抗体偶联药物的研究进展
- Author:
Yuning LI
1
,
2
;
Jialin SU
;
Shuhua TAN
;
Yongzhong LUO
;
Lemeng ZHANG
Author Information
1. 湖南省肿瘤医院胸部内一科,长沙 410013
2. 湖南科技大学生命科学与健康学院,湖南 湘潭 411201
- Keywords:
antibody drug conjugates;
cancer;
bi-specific;
site-specific;
dual payload;
pro-drug type
- From:
Journal of Central South University(Medical Sciences)
2024;49(2):296-304
- CountryChina
- Language:Chinese
-
Abstract:
Traditional antibody drug conjugates(ADC)combine monoclonal antibodies with cytotoxic drugs to accurately strike cancer cells,but there are still many shortcomings in stability,targeting,efficacy,and safety.Novel ADC,such as bi-specific,site-specific,dual-payload,and pro-drug type ADC,can be optimized by simultaneously binding 2 different antigens or epitopes,selecting more stable linkers,coupling with specific amino acid sites of antibodies,carrying different drug payloads,and adopting prodrug strategies,while retaining the characteristics of traditional ADC.Significantly improving the stability,targeting,efficacy and safety of drugs can better meet the needs of clinical treatment.Novel ADC will play a more important role in cancer treatment in the future.Discussing the progress of novel ADC in cancer treatment and analyzing their advantages and challenges can provide theoretical support for the development of anti-cancer strategies and provide directions for drug research and development.
